Background And Aims The serological responses after severe acute respiratory syndrome
coronavirus 2 vaccination may be attenuated in immunocompromised individuals. The study …

Introduction There are concerns regarding the effectiveness and safety of SARS‐CoV‐2
vaccine in inflammatory Bowel Disease (IBD) patients. This systematic review and meta …

METHODS: We performed a prospective study to evaluate humoral immunogenicity among
patients with IBD and HCs after completion of mRNA COVID-19 vaccines. RESULTS: One …

Lay Summary T-cell and antibody responses to severe acute respiratory syndrome
coronavirus 2 vaccination in inflammatory bowel disease patients are poorly correlated. T …

METHODS: In this prospective cohort of SARS-CoV-2 immunized patients with IBD, we
evaluated associations between participant age, sex, vaccine type, medication use, and the …

Background Patients with inflammatory bowel disease (IBD) on immune-modifying treatment
could be at an increased risk for severe coronavirus disease 2019 (COVID-19); thus, data on …

Severe acute respiratory syndrome coronovirus-2 (SARS-CoV-2) is the cause of the
coronavirus disease 2019 (COVID-19) pandemic. Vaccination is considered the core …

Background Some patients with inflammatory bowel disease (IBD) on immunosuppressive
therapies may have a blunted response to certain vaccines, including the messenger RNA …

Covid-19 is a pandemic disease that is more severe and mortal in people with
immunodeficiency, such as those with inflammatory bowel disease (IBD). On the other hand …

Background: In the coronavirus disease 2019 (COVID-19) pandemic, severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination has been effective in …